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Background: Individuals with single-sided deafness (SSD) have problems with speech perception in noise,
localisation of sounds and with communication and social interaction in their daily life. Current treatment modalities
(Contralateral Routing of Sound systems [CROS] and Bone Conduction Devices [BCD]) do not restore binaural
hearing. Based on low level of evidence studies, CROS and BCD do not improve speech perception in noise or
sound localisation. In contrast, cochlear implantation (CI) may overcome the limitations of CROS and BCD, as
binaural input can be restored. Promising results have previously been achieved on speech perception in noise,
sound localisation, tinnitus and quality of life.
Methods and design: A single-center Randomised Controlled Trial (RCT) was designed to compare all treatment
strategies for SSD. One hundred and twenty adult single-sided deaf patients (duration of deafness >3 months and
maximum 10 years; pure tone average at 0.5, 1, 2, 4 kHz, deaf ear: threshold equal to or more than 70 dB, better
ear: threshold of maximum 30 dB) will be included in this trial and randomised to CI, ‘first BCD, then CROS’ or ‘first
CROS, then BCD’-groups. After the trial period, patients in the two latter groups may choose with which treatment
option they continue. Outcomes of interest are speech perception in noise, sound localization, tinnitus and quality
of life. These outcomes will be measured during a baseline visit and at follow up visits, which will take place at 6,
12, 18, 24, 36, 48 and 60 months after onset of treatment. Furthermore, an economic evaluation will be performed
and adverse events will be monitored.
Discussion: This RCT allows for a comparison between the two current treatment modalities for single-sided
deafness and a new promising treatment strategy, CI, on a range of health outcomes: speech perception in noise,
sound localization, tinnitus and quality of life. Additionally, we will be able to answer the question if the additional
costs of CI are justified by increased benefits, when compared to current treatment strategies. This study will inform
health policy makers with regard to reimbursement of CI.
Trial registration: Netherlands Trial Register (www.trialregister.nl): NTR4580.
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Individuals with single-sided deafness (SSD) have prob-
lems with speech perception in noise and localisation of
sound [1, 2]. With only one functional ear, they cannot
benefit from binaural summation (redundancy of audi-
tory input) [3] and squelch effects (ability of the brain to
separate sound and noise signals from spatially sepa-
rated sources) [1, 2]. Moreover, the head acts as an
acoustic barrier and thus attenuates signals from the
deaf side going to the better ear, known as the geometric
head shadow effect [4]. Patients suffering SSD experi-
ence problems in their daily life in social interaction and
communication [5].
Current treatment modalities for patients with SSD
are Contralateral Routing of Sound (CROS) systems and
Bone Conduction Devices (BCD). A CROS conducts sig-
nals from the hearing field of the poor ear via a wire (or
FM/Bluetooth) to an output transducer in the ear canal
of the better ear such that sound awareness is restored.
A BCD transfers signals from the hearing field of the poor
side to the better hearing ear by vibration of the skull bone
via a titanium implant. A trial with a BCD can be per-
formed by attaching the BCD to a tight headband. Theor-
etically, CROS and BCD can alleviate the head shadow
effect. However, neither modality can restore binaural
hearing. A recently published review found that there
are no high level of evidence studies comparing CROS
and BCD for single-sided deafness [6]. The authors of
the review could only include studies with low to mod-
erate levels of evidence, and they found that CROS and
BCD did not improve speech perception in noise or sound
localisation, although patients did benefit in speech com-
munication subjectively [6].
A new treatment option for single-sided deafness, coch-
lear implantation, may overcome the limitations of CROS
and BCD. Since cochlear implantation restores auditory
input on the impaired side, binaural input can be restored.
Speech perception in noise and sound localisation im-
proved in patients with single-sided deafness treated with
a cochlear implant (CI) [7–9]. Furthermore, cochlear im-
plantation may reduce tinnitus and improve quality of life
[10]. However, the quality of the studies included in
these reviews was suboptimal: sample sizes were small,
study designs were case series and they were prone to
selection bias [11].
The reviews on both current and new treatment op-
tions for single-sided deafness make clear that high level
of evidence studies are warranted. Therefore, we initi-
ated a Randomised Controlled Trial (RCT) comparing
CROS, BCD and CI for SSD. Outcomes of interest are
speech perception in noise, sound localization, quality of
life and tinnitus. Finally, an economic evaluation will be
performed. Since cochlear implantation is more expen-
sive than current treatment options, it is important toknow whether the promising results of cochlear implant-
ation outweigh the additional costs.
Methods
Study objectives
The main objective of our study is to compare CROS,
BCD and CI in patients with SSD evaluating speech per-
ception in noise, sound localization, quality of life and tin-
nitus. The second objective is to perform an economic
evaluation and to evaluate adverse events in all groups.
Study design
In this RCT patients are randomised in three groups.
For a schematic overview of the study, see Fig. 1.
We will now discuss all consecutive steps in the study
design as included in this study protocol. This protocol is
reported according to the SPIRIT Statement, an inter-
national guideline on the reporting of study protocols [12].
Study population
The study population consists of patients who present
with SSD at the outpatient department of our tertiary
referral center, the University Medical Center Utrecht,
Utrecht, The Netherlands. They must meet the following
criteria to be eligible for the study.
Inclusion criteria
– Age 18 years or older
– Audiometry (Pure Tone Average [PTA] at 0.5, 1,
2, 4 kHz)
○ Deaf ear: threshold of ≥70 dB
○ Better ear: threshold of ≤30 dB
○ Air bone gap ≤10 dB (to ensure normal middle
ear function)
– Duration of deafness >3 months and ≤10 years
– Health status allows general anaesthesia and surgery
for the potential implantation of BCD or CI
– Dutch language proficiency
– Coverage of Dutch health insurance
– Willingness and ability to participate in all scheduled
procedures outlined in the protocol
The minimum duration of deafness is 3 months, since
that is the time in clinical practice to await the natural
course of sudden deafness. The maximum duration of
deafness is up to 10 years, since degeneration of the audi-
tory nerve may occur.
Exclusion criteria
– Previous experience with implanted BCD or CI
– Retrocochlear pathology
– Abnormal cochlear anatomy (i.e. ossification)
Fig. 1 Flow diagram of CINGLE-trial. Abbreviations: BCD = Bone Conduction Device (* indicates trial period on headband), CI = Cochlear Implant,
CROS = Contralateral Routing of Sound system, mo =months, wk = weeks
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○ which could interfere with the completion of
the tests or questionnaires (e.g. psychiatric)
○ with an expected survival of less than five years
If eligible for inclusion, an Informed Consent (IC) form
will be signed by patient and researcher. Only after IC, a
CT-scan of the mastoid will be made, if none is available
yet, to assess cochlear anatomy and check if no contrain-
dications to cochlear implantation (e.g. ossification) exist.
Since the anatomical situation must allow cochlear im-
plantation (and thus randomisation), CT-scans will be per-
formed prior to randomisation.
Randomisation and interventions
A web-based randomisation tool (Julius Center, University
Medical Center Utrecht, Utrecht, The Netherlands) will
be accessed via a computer by one of the members of the
research team. Patients will be randomised into groups A,
B and C (see Fig. 1), using a block size of 8 and a ratio
of 2:3:3 for groups A:B:C and stratified for age (<45
years, ≥45 years). Blinding and concealed treatment al-
location is not possible in our study design.
In group A, patients will be implanted with a CI from
Cochlear Ltd., (type CI422). A retro-auricular incision is
made to expose the mastoid. The electrode is inserted
via a posterior tympanotomy and round window implant-
ation. Intraoperatively, normal functioning of the device is
checked by measurement of impedance and neural re-
sponse telemetry. Four weeks after implantation, the CI
will be activated by an experienced audiologist. In the re-
habilitation phase, patients will be encouraged to use the
CI each day and will be trained by experienced speech and
language therapists. Patients are instructed to train the
cochlear implant ear using an International Speech Test
Signal (ISTS) noise [13] via an insert earphone to mask
the better ear.
In the Netherlands, a trial period with both CROS and
BCD is standard clinical care. Patients in groups B and C
try both devices for 6 weeks: group B starts with the BCD
(type: BP110, Cochlear Ltd.), then CROS (Phonak Audeo
Q50-312T and CROS H2O), whereas patients in group C
start with the CROS and then try the BCD. The reversed
order is implemented to correct for the order effect: pa-
tients judge their second hearing aid based on experiences
with the first hearing aid. After these two trial periods, pa-
tients may, according to clinical practice, choose which of
both treatments they like best. When they choose a BCD,
the implant and abutment will be surgically implanted, and
after six weeks mounted with a BCD (type: BAHA 4 sys-
tem, Cochlear Ltd.). When they prefer CROS, the patient
is referred to standard clinical care where the CROS will
be adjusted. Patients can also opt for no treatment if none
is preferred, according to standard clinical health care.Sample size
To detect a clinically relevant difference of 5 dB signal-
to-noise ratio (SNR) (standard deviation 5 dB) between
the groups on the primary outcome (see Outcomes), with
an alpha of 0.05 and a power of 95%, 27 subjects per group
are needed. To compensate for potential dropouts, a 10%
margin is implemented, resulting in 30 patients in group
A. Initial group distribution will be n = 45 for groups B and
C. These groups are bigger, since previous studies describe
that only 45% of BCD-on-headband users are satisfied after
their trial period and opt for a BCD implantation (n ~ 45)
[14]. Therefore, we will include more patients in groups B
and C than in group A. Patients not choosing a BCD can
opt for a CROS (approximately 60% of remaining patients,
n ~ 30). The rest of the patients (n ~ 20) will probably pre-
fer no treatment; they will be followed up to assess the nat-
ural course of single-sided deafness.
Approximately 25–30 patients per year present with
SSD at the otorhinolaryngological outpatient department
of our tertiary referral center. We will actively invite au-
diologic centers in the neighborhood to refer patients to
our clinic. Therefore, we expect the inclusion period to
last for ~3 years.
Outcomes
The following outcome measurements will be recorded
during baseline visit (one condition, i.e. ‘no device’) and
follow up visits at 6, 12, 18, 24, 36, 48 and 60 months
‘device on’. During all audiometric tests, patients will be
instructed not to move their heads to improve speech
perception or sound localisation. Head movements will
be checked by the researcher conducting the experi-
ments. Patients will not receive feedback on their per-
formance on audiometric tests. All experiments will be
performed by researchers following the same protocol
procedures.
Primary outcome measure
Our primary outcome is the performance on speech per-
ception in noise, measured with the Utrecht Sentence Test
with Adaptive Randomized Roving Levels (U-STARR) [15].
In short, the U-STARR is designed to determine a patient’s
ability to understand speech in a noisy environment (sig-
nal from front, noise from front: S0N0. See Fig. 2, test set-
up York Crescent of Sound [16]). A sentence is considered
to be understood correctly when ≤2 words are repeated
incorrectly. The noise level starts at +20 dB (roving 65–75
dB SPL). When the sentence is repeated correctly, the
level of the noise increases for the next sentence. Noise is
presented 500 ms before the start of the sentence and
ends 500 ms after the sentence. Sentences used are trad-
itional Dutch sentences from everyday life [17]. The test
provides a critical SNR at which 50% of sentences is
understood correctly (in dB).
Fig. 2 Set-up York Crescent of Sound. The patient is positioned in the center of an arch of loud speakers (-90 to 90°) at head level with a radius
of 1.45 m [16]
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Speech perception in noise Speech perception in noise
is measured in two more configurations: S−60N+60 and
S+60N-60 (Fig. 2). Again, Dutch sentences are used in
the same audiometric set-up as the U-STARR [15, 17]
leading to a SNR (in dB).
Sound localisation The ability to localise sounds is also
measured with the York Crescent of Sound set-up [16].
The stimulus (sentence by female speaker: ‘Hello, what’s
this?’) is presented in quiet at a roving level of 55–65 dB
SPL in three configurations: 5 boxes separated by an angle
of 15° (box -30°, box -15°, box 0°, box +15° and box +30°),
5 boxes separated by an angle of 30° (box -60°, box -30°,
box 0°, box +30° and box +60°) and 3 boxes separated by
an angle of 60° (box -60°, box 0° and box +60°) (Fig. 2).
The patient must indicate from which box the stimulus
came. The test outcome is a percent correct score.
Tinnitus Tinnitus burden will be assessed using three
questionnaires:
– Tinnitus Handicap Inventory (THI): a 25-item
questionnaire with statements/questions about
tinnitus burden [18]. Possible answers are ‘Yes’ (4
points), ‘Sometimes’ (2 points) and ‘No’ (0 points),
resulting in a maximum score of 100, representing
a maximum burden of tinnitus. The inventory is
divided in a functional, emotional and catastrophic
subscale.
– Tinnitus Questionnaire (TQ): a 52-item questionnaire
consisting of 5 subscales: emotional and cognitive
distress, intrusiveness, auditory perceptual difficulties,
sleep disturbances and somatic complaints [19, 20].
Possible answers are ‘Yes’ (2 points), ‘Sometimes’(1 point) and ‘No’ (0 points). Of the 52 questions, 38
constitute a final TQ-score on the validated Dutch
version of the TQ [21]. Tinnitus can be graded mild
(TQ 0–16), moderate (TQ 18–34), severe (TQ 34–56)
and catastrophic (TQ >58).
– Tinnitus Burden Questionnaire (TBQ): this is a
self-developed questionnaire assessing various as-
pects of tinnitus burden. It consists of 12 visual
analogue scales (VAS), ranging from ‘0’ (no tinnitus
burden) to ‘10’ (maximum tinnitus burden).
Quality of life Participants will be asked to fill in several
questionnaires, each assessing different parts of QoL.
– Speech, Spatial and Qualities of hearing scale (SSQ):
this questionnaire assesses three domains of hearing:
1) Speech: consists of 15 questions about the ability
to separate speech from competing noise in a wide
range of listening contexts; 2) Spatial: consists of
17 questions to assess the ability to locate sound
sources and their direction of movement; 3) Quality:
consists of 19 questions that assess naturalness and
clarity of sounds. The responses are given on a
VAS ranging from 0 (not able to) to 100 (perfectly
able to) [22].
– Abbreviated Profile for Hearing Aid Benefit
(APHAB): this 24-item questionnaire documents the
outcome of a hearing aid [23]. The questionnaire
yields scores on subscales for ease of communication,
listening under reverberant conditions, listening in
background noise and aversiveness of sound.
– Glasgow Benefit Inventory (GBI): a measure of
patient benefit developed especially for
otorhinolaryngological interventions [24]. The
inventory is validated to measure outcomes on
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procedures. It measures QoL in three domains:
social, general and physical. The domains score on a
scale of -100 to 100 (minimum versus maximum
benefit, respectively).
– Hospital Anxiety Depression Scale (HADS): a
screening tool for anxiety and depression in
non-psychiatric clinical populations [25]. We use
the HADS to measure baseline depression
symptoms, which may confound/bias the results of,
for instance, tinnitus burden.
– A VAS consisting of two questions (quality of life,
quality of hearing).
– Time Trade Off (TTO): comprises one question
about how many years of their lives patients would
sacrifice for living with perfect hearing for the rest
of their lives. TTO (%) = ((life expectancy – number
of years to give up for perfect hearing) / life
expectancy) * 100. This question is generally
considered a difficult question, so it will not be
presented on paper, but asked during the baseline
and follow up visits.
– EuroQoL5D (EQ5D): is a measure of general health
status [26]. It contains 5 questions on mobility,
self-care, daily activities, pain/complaints, anxiety/
depression and a scale to denote general quality
of life (VAS 1–10). We will use the Dutch EQ5D
tariff [27].
– Health Utilities Index 3 (HUI3): this is a generic
quality of life questionnaire consisting of 8 domains:
vision, hearing, speech, ambulation, dexterity,
cognition, emotion and pain [28].
Economic evaluation The latter three questionnaires
can be used to calculate utility. Utility reflects the value
that is attached to health status. Utility values are im-
portant for the calculation of Quality Adjusted Life Years
(QALYs), which serve as the denominator for the Incre-
mental Cost Utility Ratio (ICUR). The ICUR is calculated
as the incremental costs of cochlear implantation as com-
pared to current treatments (numerator) divided by the
incremental effects in terms of QALYs. Costs will be mea-
sured from a societal and health care perspective. Both
direct health care costs and indirect non-health care costs
will be incorporated in the analyses. Both categories of
costs will be quantified using a cost diary. This diary is
completed on a monthly basis the first 2 years and on a
quarterly basis the last three years. This diary assesses
costs related to hospitalisation, surgery, blood tests, com-
plications (direct health care costs) and sick leave, time
and travel costs (indirect health care costs). Unit prices for
volumes of resources use will be taken from the Dutch
guidelines for costing research in health economic evalua-
tions, as issued by the National Healthcare Institute [29].Incremental Cost Utility Ratios, comparing CI with CROS
and BCD, will be estimated using bootstrapping. Cost-
effectiveness planes and a cost-effectiveness acceptability
curve will be plotted to visually represent the results of
the economic evaluation.
In addition to these outcome measurements at the pre-
viously specified baseline and follow up visits, we will also
objectify the experiences of the patients in Groups B and
C in the trial periods with CROS and BCD (see Fig. 1).
To minimize patient burden, only the APHAB, GBI and
SSQ questionnaires will be administered to evaluate
these trial periods.
Statistical analysis
Baseline characteristics per group will be described as
means and standard deviations. Differences between
the three groups will be analysed using the Kruskal
Wallis test.
The data of our primary outcome are quantitative and
will be presented as continuous variables. Between-group
mean differences, rate differences and rate ratios with 95%
confidence intervals will be calculated. Again, the Kruskal
Wallis test will be used to analyse differences between
the groups.
The secondary outcomes contain both categorical and
continuous outcomes. Analyses of between-group differ-
ences will be performed with Chi-square-tests for categor-
ical outcomes and Kruskal Wallis tests for continuous
outcomes. Within-subject comparisons will entail differ-
ences of mean values. These will be analysed using paired
t-tests for continuous measures.
Major test intervals are the same in all study groups
(baseline and 6, 12, 18, 24, 36, 48, 60 months follow up;
6 and 12 weeks for group B and C). Missing values will
be imputed using multiple imputation. All analyses will
be performed on an intention-to-treat basis. A signifi-
cant result is defined as a p-value < 0.05. Statistical pack-
age SPSS will be used for statistical analyses of the data.
Data will be presented according to the Consolidated
Standards of Reporting Trials (CONSORT) Statement,
an international guideline on adequate reporting RCTs
[30, 31].
Safety
This study will be conducted in accordance with the most
recent version of the Declaration of Helsinki (Fortaleza,
2013), good clinical practice guidelines and the Medical
Research Involving Human Subjects Act of the Dutch
government. The research protocol was approved by the
Institutional Review Board (IRB) of the University Med-
ical Center Utrecht (NL45288.041.13; version 3, April
2nd, 2014).
All cases of serious adverse events will be reported to
the local IRB and adequately followed up. An independent
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Netherlands) is appointed to check trial quality (complete-
ness of IC, validity of data etc.) twice a year. All patient
data will be stored on a password protected computer in a
lockable room. In the same room the signed Informed
Consent forms will be kept in a locked cabin.
Trial status
The trial is currently in recruitment phase.
Discussion
Patients suffering SSD experience problems with speech
perception in noise and localisation of sound and in so-
cial interaction and communication [5].
Current treatment modalities do not restore binaural
hearing for patients with SSD. A recently published review
concluded that there are no high quality studies comparing
CROS and BCD for single-sided deafness [6]. With this lim-
ited level of evidence, CROS and BCD did not improve
speech perception in noise or sound localisation. Patients
did benefit in speech communication subjectively. Cochlear
implantation may overcome the limitations of CROS and
BCD, as binaural hearing can be restored. Promising results
have previously been achieved on speech perception in
noise, sound localisation, tinnitus and quality of life [7–11].
The current study is the first high level of evidence
trial to be conducted to effectively compare all treatment
strategies for single-sided deafness. One hundred and 20
adult single-sided deaf patients will be included in this
trial and randomised to CI, BCD-CROS or CROS-BCD
groups (Fig. 1). Outcomes of interest are speech percep-
tion in noise, sound localization, quality of life and tin-
nitus. Finally, an economic evaluation will be performed
to answer the question if the additional costs of cochlear
implantation are justified by increased benefits compared
to current treatment strategies.
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